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Abstract
Cryptosporidium parvum (Cp) is a potential biowarfare agent and major cause of diarrhea and
malnutrition. This protozoan parasite relies on inosine 5′-monophosphate dehydrogenase
(IMPDH) for the production of guanine nucleotides. A CpIMPDH-selective N-aryl-3,4-dihydro-3-
methyl-4-oxo-1-phthalazineacetamide inhibitor was previously identified in a high throughput
screening campaign. Herein we report a structure-activity relationship study for the phthalazinone-
based series that resulted in the discovery of benzofuranamide analogs that exhibit low nanomolar
inhibition of CpIMPDH. In addition, the antiparasitic activity of select analogs in a Toxoplasma
gondii model of C. parvum infection is also presented.
Cryptosporidium species cause self-limiting gastrointestinal disease that can be chronic and
fatal in immunosuppressed patients 1. Oocysts from these organisms are resistant to
common methods of water treatment, and therefore pose a potential biowarfare threat. The
drugs currently approved for the treatment of cryptosporidiosis are largely ineffective,
elevating the need for new chemotherapeutic agents to counter outbreaks. Genomic analysis
of the most common human pathogens, C. parvum and C. hominis, revealed that these
parasites have a streamlined purine salvage pathway that relies on IMP dehydrogenase
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(IMPDH) for the production of guanine nucleotides 2–4. This enzyme catalyzes the oxidation
of IMP to XMP with the production of NADH as outlined in Scheme 15. Curiously, the
Cryptosporidium IMPDH gene appears to have been obtained from an ε-proteobacterium
via horizontal gene transfer 6, and is structurally distinct from the host ortholog (the C.
parvum and C. hominis enzymes are identical and will be denoted as CpIMPDH).
Consequently, CpIMPDH displays unique enzymatic properties compared with the host
counterparts 7.
A previously reported high throughput screening (HTS) campaign identified several
structurally distinct classes of selective CpIMPDH inhibitors that bind to the NAD site 8, 9.
Structure-activity relationship studies of triazole 10, benzimidazole 9, 11 and urea 12
CpIMPDH inhibitors, exemplified by A110, C64, C97 and P96, respectively, have also now
been reported (Figure 1). In addition, a co-crystal structure of the benzimidazole inhibitor
C64 with CpIMPDH demonstrated a unique binding mode compared to inhibitors bound to
human IMPDH 9. The phthalazinone-based inhibitor 1 was also identified by HTS, with
moderate potency (IC50 = 5.4 μM) and good selectivity (IC50 > 50 μM versus both human
IMPDH1 and IMPDH2) 8. Compound 1 (50 μM) did not display antiparasitic activity 8.
Herein we report a structure-activity relationship study of 1, and the antiparasitic activity of
select analogs in a T. gondii model of C. parvum infection.
Compound 1 and its analogs were prepared following a four-step sequence as depicted in
Scheme 2 beginning with the Wittig olefination of phthalic anhydride, 2, in the presence of
carbethoxymethylidenetriphenylphosphorane in chloroform to produce (E)-ethyl-2-(3-
oxoisobenzofuran-1(3H)-ylidene)acetate, 3. Addition of hydrazines in refluxing ethanol
generated the phthalazinone acetoesters 4. Hydrolysis of the esters produced phthalazinone
acetic acids 5 13, 14. Finally, coupling of the acetic acid moiety with various aromatic amines
in DMSO afforded 6.
The synthesized derivatives were evaluated for CpIMPDH inhibition using an assay that
monitored the production of NADH in the presence of varying inhibitor concentrations 10. In
order to evaluate the effects of non-specific binding, inhibition was also determined in the
presence of 0.05% fatty acid free bovine serum albumin (BSA). None of the compounds
inhibited human IMPDH2 (IC50 > 5 μM).
Inhibitor 1 exhibited an IC50 of 1.0 μM upon resynthesis. Gratifyingly, the activity was
retained in the presence of 0.05% BSA (IC50 = 970 nM) as shown in Table 1. However,
moving the electron donating group to the 2- or 3-position resulted in loss of activity (7 and
10). Replacing the 4-OMe with a variety of other electron donating substituents (11 – 14)
was also detrimental. Likewise, replacing the phenyl with an amine (8) or alkyl group (9) or
inserting a methylene between the benzene and amide nitrogen atom (15) was not tolerated.
Replacement of the electron donating group at the 4-position with electron withdrawing
groups improved potency. For example, the 4-chloro and 4-bromo analogs (16 and 17)
demonstrated IC50 values of 230 and 130 nM, respectively. However, other electron
withdrawing groups (18 – 21) generally were not as well tolerated. Also, transposition of the
chlorine from the 4-position to the 3-position (23) resulted in loss of activity. Di-substitution
at the 3,4-positions with chlorine and bromine atoms (24 and 25) resulted in increased
potency. Furthermore, other 3,4-di-substituted analogs with either an electron-donating or an
electron-withdrawing group at the 3-position were also active. Interestingly, in a number of
cases substituents at the 3-position that alone were not tolerated when combined with
electron withdrawing groups (especially Cl or Br) at the 4-position resulted in potent
CpIMPDH inhibitors (e.g. 26, 27 and 37). However, transposition of the substituents from
the 3-position to the 2-position (39 – 42) resulted in poor inhibitors. In addition, several
other di- and tri-substitutions (43 – 46) were also detrimental. Encouraged by the results of
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3,4-disubstitution, the 2-naphthyl analog 47 was prepared and demonstrated an IC50 of 63
nM. Similar increases in CpIMPDH activity by introduction of 3,4-disubstitution or
incorporation of 2-naphthylene had also been observed in the structure-activity relationship
studies resulting in A110 and C97 10, 11. Finally, analogs that lack methylation of the
phthalazinone nitrogen atom (48 and 49) were found to be active indicating that this
substituent is not necessary for CpIMPDH inhibitory activity.
Inspired by the results with 47, a variety of fused heterocycles were explored as
replacements of the 2-naphthylene (Table 2). Although the 5-benzofuranyl analog 50 had
reduced activity and the 5-benzoxazolyl analog 51 was inactive, the 2-methyl-5-
benzofuranyl derivative 52 retained activity with an IC50 of 64 nM. Furthermore,
incorporation of an additional ring (53) resulted in enhanced potency. Unsaturation of the
ring further increased activity with 54 demonstrating an IC50 of 4 nM. However, the
regioisomer 55 and two carbazoles 56 and 57 were not active.
Compounds with IC50 values less than 30 nM were candidates for evaluation of antiparasitic
activity in a Toxoplasma gondii model of C. parvum infection 15. In this model, the
endogenous T. gondii IMPDH and hypoxanthine-guanine-xanthine
phosphoribosyltransferase genes have been knocked out and the CpIMPDH gene inserted to
create T. gondii/CpIMPDH, a model parasite that relies on CpIMPDH for the production of
guanine nucleotides. Both wild-type and T. gondii/CpIMPDH were cultured in human
foreskin fibroblasts immortalized with hTERT, so this assay also reports on host cell
toxicity. Compounds 26, 27, 53 and 54 all displayed sub-micromolar activity against T.
gondii/CpIMPDH (Table 3). However, only 27 displayed selectivity • 30 versus the wild-
type strain, strongly indicating that antiparasitic activity results from the inhibition of
CpIMPDH.
The inhibition of CpIMPDH by compound 27 was characterized further. Whereas
compound 1 is a mixed inhibitor of CpIMPDH with respect to NAD+ (Kis = 1.8 μM, Kii =
7μM) 8, 27 is a pure noncompetitive inhibitor (Kis = Kii = 3.4 ± 0.2 nM; Figure 2).
Compound 27 displayed good stability in mouse liver microsomes (T1/2= 79 min). This
compound was advanced into the IL12 knockout mouse model of C. parvum infection 16–19.
Disappointingly, no antiparasitic activity was observed with once per day oral dosing of 27
(250 mg/kg) for seven days. It may be that alternative dosing regimes or modifications in
formulations could improve efficacy in vivo. Additional optimization of pharmacokinetic
properties may also be necessary for this compound series in order to achieve in vivo
efficacy.
In conclusion, a SAR study of phthalazinone-based CpIMPDH inhibitors revealed that
expansion of the aniline ring could increase inhibitory activity, while maintaining selectivity
relative to the human orthologs. The phthalazinone-based CpIMPDH inhibitors described
herein could serve as lead compounds for the development of effective treatments of
cryptosporidiosis as well as useful molecular probes for studying Cryptosporidium parasites.
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Optimized CpIMPDH inhibitors A110, C64 and C97 and HST identified CpIMPDH
inhibitor 1.
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Inhibition of CpIMPDH by 27.
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IMPDH catalyzed conversion of IMP to XMP via intermediate E-XMP*.
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General procedure for the synthesis of phthalazinone derivatives of 1. a) Ph3PCHCO2Et,
CHCl3, reflux, 16 h. b) NH2NH2 or NH2NHMe, EtOH, reflux, 3 h. c) 3 M NaOH/THF,
reflux, 2 h followed by acidification. d) R1-NH2, EDC, HOBt, DIPEA, DMSO, 3–5 h.
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Table 1
SAR of anilide and nathylide phthalazinone inhibitors
Assays as described in 10.
Compound R R1 (−)-BSA (nM) (+)-BSA (nM)
1 Me 4-OMePh 1000 ± 200 930 ± 180
7 Me 2-OMePh >5000 ND
8 Me NH2 >5000 ND
9 Me t-Bu >5000 ND
10 Me 3-OMePh >5000 ND
11 Me 4-OEtPh >5000 ND
12 Me 4-OCF3Ph >5000 ND
13 Me 4-MePh >5000 ND
14 Me 4-i-PrPh >5000 ND
15 Me CH2(4-OMePh) >5000 ND
16 Me 4-ClPh 230 ± 50 280 ± 50
17 Me 4-BrPh 130 ± 30 130 ± 20
18 Me 4-FPh >5000 ND
19 Me 4-CNPh 950 ± 90 940 ± 90
20 Me 4-CF3Ph >5000 ND
21 Me 4-SO2MePh >5000 ND
22 Me 3-CF3Ph >5000 ND
23 Me 3-ClPh >5000 ND
24 Me 3,4-di-ClPh 55 ± 6 95 ± 2
25 Me 3-Cl-4-BrPh 30 ± 1 75 ± 2
26 Me 3-CF3-4-BrPh 24 ± 2 48 ± 4
27 Me 3-CF3-4-ClPh 13 ± 1 25 ± 5
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Compound R R1 (−)-BSA (nM) (+)-BSA (nM)
28 Me 3-CF3-4-CNPh 54 ± 5 52 ± 6
29 Me 3-Cl-4-CNPh 290 ± 40 470 ± 120
30 Me 3-CF3-4-FPh 150 ± 20 150 ± 30
31 Me 3-CF3-4-OMePh >5000 ND
32 Me 3-CF3-4-NH2Ph >5000 ND
33 Me 3-F-4-ClPh 200 ± 30 240 ± 30
34 Me 3-Me-4-ClPh 79 ± 9 96 ± 19
35 Me 3-Me-4-BrPh 70 ± 10 140 ± 10
36 Me 3-Me-4-CNPh 400 ± 100 460 ± 90
37 Me 3-OMe-4-ClPh 33 ± 1 40 ± 7
38 Me 3,4-di-CNPh >2500 >2500
39 Me 2-CF3-4-ClPh >5000 ND
40 Me 2-CF3-4-BrPh >5000 ND
41 Me 2-F-4-BrPh 1100 ± 200 1700 ± 100
42 Me 2,4-BrPh >5000 ND
43 Me 2,4-di-ClPh >5000 ND
44 Me 3,5-di-ClPh >5000 ND
45 Me 3,4,5-tri-ClPh >5000 ND
46 Me 3,4,5-tri-FPh >5000 ND
47 Me 2-naphthyl 63 ± 3 140 ± 20
48 H 3-CF3-4-ClPh 40 ± 1 61 ± 1
49 H 3-CF3-4-BrPh 32 ± 6 130 ± 8
All values are average of three independent determinations unless otherwise noted (* two determinations). ND, not determined.
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Table 2
SAR of heterotricyclic anilide phthalazinone inhibitors
Assays as described in 10.
Compound R (−)-BSA (nM) (+)-BSA (nM)
50 93 ± 15 85 ± 12
51 >5000 ND
52 64 ± 11 72 ± 15
53 20 ± 5 150 ± 20
54 4 ± 1 30 ± 10
55 >5000 ND
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Compound R (−)-BSA (nM) (+)-BSA (nM)
56 >5000 ND
57 >5000 ND
All values are average of three independent determinations unless otherwise stated. ND, not determined.
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Table 3
Antiparasitic activity





26 4 ± 3 * 0.3 ± 0.2 14
27 23 ± 4 0.4 ± 0.3 60
53 1 ± 1 * 0.5 ± 0.2 2
54 3 ± 1 0.4 ± 0.1 7
Values are the average and standard deviations of three independent determinations unless otherwise stated
*denotes average and range of two determinations).
aT. gondii RH (Toxo/WT) should be resistant to CpIMPDH inhibitors while T. gondii/CpIMPDH (Toxo/CpIMPDH) should be sensitive.
bSelectivity = EC50(Toxo/WT)/EC50(Toxo/CpIMPDH).
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